CoreWeave, Inc. (CRWV) Spending and interest coverage
- R&D / revenue · 12 months: Value 5.57%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 8.16%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 5.57% | Research and development expense / revenue. Period ending 2026-06-30. $423.00M ÷ $7.59B × 100 ≈ 5.57% |
| Stock-based compensation / revenue · 12 months | 8.16% | Share-based compensation / revenue. Period ending 2026-06-30. $619.00M ÷ $7.59B × 100 ≈ 8.16% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 423.00M USD | Research and Development Expense |
| Revenue | 7.59B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 619.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -231.00M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $423.00M | $7.59B | $619.00M | $-231.00M | (m) | 5.57% | 8.16% | (m) | (m) |
| 2026-03-31 | $386.00M | $6.23B | $599.00M | $-163.00M | (m) | 6.20% | 9.62% | (m) | (m) |
| 2025-12-31 | $352.00M | $5.13B | $630.00M | $-46.00M | (m) | 6.86% | 12.28% | (m) | (m) |
| 2025-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $56.00M | $1.92B | $31.00M | $324.00M | (m) | 2.92% | 1.62% | (m) | (m) |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $21.00M | $229.00M | $15.00M | $-14.00M | (m) | 9.17% | 6.55% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.